17 June - 21 June

ICML 2025

LUGANO

We are excited to be at ICML 2025 to share our latest data, and engage and learn with the scientific community, solidifying our goal to bring the promise of cell therapy to as many eligible patients as possible.

To learn more about our cell therapy abstracts and data, please visit the congress website.

CIBMTR 3L+ Richter Transformation

Real-World Outcomes of Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Richter Transformation to Large B-Cell Lymphoma (RT-LBCL)

Allison M. Winter et al
Thursday, June 19 17:15 CEST
Focus on: NEW CELLULAR THERAPIES
KITE-363 Phase 1 (Encore

A Phase 1 Study of KITE-363 anti-CD19/CD20 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients (pts) with Relapsed/Refractory (R/R) B-cell Lymphoma (BCL)

Saurabh Dahiya et al
Wednesday, June 18 17:00 CEST
Focus on: NEW CELLULAR THERAPIES

CIBMTR Bendamustine as Lymphodepletion

Bendamustine as Lymphodepleting Chemotherapy (LDC) Prior to Axicabtagene Ciloleucel (Axi-Cel) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL)

Alaa Ali et al
Wednesday, June 18
12:00-18:00 CEST Marquee Parco Ciani
Axi-cel CNSL

A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL)

Jacobson CA et al

Axi-Cel Health Impact Projection in Portugal
784

Impact on Health Outcomes of Treating All Eligible Patients with Axicabtagene Ciloleucel in Portugal - a Modeling Approach

Aragao F et al
PRIME-CAR PMBCL Germany
837

Axicabtagene Ciloleucel CAR T-Cells in Patients with relapsed or refractory primary mediastinal B-Cell Lymphoma

Imke E. Karsten et al
LATE-R trial
841

LATE-R trial: A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy of Axi-cel in Patients with Late Relapse of Large B-Cell Lymphomas 

Mariana Bastos-Oreiro et al